ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2016

Abstract Number: 2995

WISP1/CCN4 Aggravates Experimental Osteoarthritis and Is Associated with Disease Progression in Early Osteoarthritis Patients

Martijn H. van den Bosch1, Arjen B. Blom1, Azusa Maeda2, Tina Kilts2, Wim B. van den Berg3, Peter L. van Lent3, Marian F. Young2 and Peter M. van der Kraan1, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2NIDCR/NIH, Bethesda, MD, 3Radboud university medical center, Nijmegen, Netherlands

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: matrix metalloproteinase (MMP), osteoarthritis and synovium, WNT Signaling

Session Information

Date: Tuesday, November 15, 2016

Title: Biology and Pathology of Bone and Joint

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:  Many osteoarthritis (OA) patients show synovial activation, which is thought to be involved in joint destruction. Previously, we described strongly increased expression of Wnt2b and Wnt16 in the synovium of two experimental OA models. In addition, we found increased Wisp1 expression, a protein induced by canonical Wnt signaling. Here, we determined whether there is a relation between synovial WISP1 expression and OA progression in a cohort study of patients with early symptomatic OA. Furthermore, we elucidated whether WISP1 plays a role during experimental OA by inducing OA models in wild type (WT) and Wisp1-/-mice.

Methods:  Microarray analysis was performed on synovium from patients in the CHECK study, initiated to follow progression of early symptomatic OA patients. Expression data were correlated with progression of OA (defined as a decrease in joint space width of ≥1mm and progression of osteophyte formation of ≥4x in size) between baseline and the five-year follow-up measurement. Human end-stage OA synovium was stimulated with WISP1. Joint pathology in WT or Wisp1-/-mice was assessed by histology after induction of collagenase-induced OA (CIOA), destabilization of the medial meniscus (DMM) and anterior cruciate ligament transection (ACLT) experimental models of OA. The aggrecan neoepitope NITEGE was visualized using immunohistochemistry. Gene expression was evaluated using qRT-PCR.

Results:  Microarray analysis of synovial tissue from patients in the CHECK cohort showed significantly increased WISP1 expression at baseline in OA progressors versus non-progressors. To determine the mechanism of how WISP1 might be involved in OA pathology, we stimulated human OA synovium with WISP1. This increased the expression of MMP2/3/9/13 and ADAMTS4/5. Next, we determined the in vivo role of WISP1. First, we found that spontaneous cartilage damage was not different between WT and Wisp1-/- mice at 3, 6 and 12 months of age. Next, we assessed joint pathology 42 days after induction of CIOA. Cartilage damage was significantly decreased in the tibio-femoral joints of the Wisp1-/- mice as compared with the WT controls. In line, we found significantly decreased cartilage degeneration in the Wisp1-/- mice in the DMM and ACLT models, 56 days after induction. In addition we found decreased expression of Mmp3/9 and the aggrecanases Adamts4/5 in the synovium, 7 days after induction of CIOA in Wisp1-/- mice, in line with the increased expression of these factors after stimulation of human OA synovium with WISP1. Whereas Wisp1-/- mice showed decreased expression of the protease inhibitor Timp1, the expression of Timp3, an important inhibitor of ADAMTS4/5, was unaffected. Finally, the protease activity in the cartilage, as assessed by the staining of the neoepitope NITEGE, was decreased in the Wisp1-/-mice.

Conclusion:  Increased WISP1 expression may play an important role in OA pathology via increased synovial MMP/ADAMTS expression. Furthermore, because of the tight regulation and complexity of Wnt signaling and its role in many physiological processes, targeting WISP1 may more specifically target OA-related pathological events, while minimizing interference with physiological processes.


Disclosure: M. H. van den Bosch, None; A. B. Blom, None; A. Maeda, None; T. Kilts, None; W. B. van den Berg, None; P. L. van Lent, None; M. F. Young, None; P. M. van der Kraan, None.

To cite this abstract in AMA style:

van den Bosch MH, Blom AB, Maeda A, Kilts T, van den Berg WB, van Lent PL, Young MF, van der Kraan PM. WISP1/CCN4 Aggravates Experimental Osteoarthritis and Is Associated with Disease Progression in Early Osteoarthritis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/wisp1ccn4-aggravates-experimental-osteoarthritis-and-is-associated-with-disease-progression-in-early-osteoarthritis-patients/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/wisp1ccn4-aggravates-experimental-osteoarthritis-and-is-associated-with-disease-progression-in-early-osteoarthritis-patients/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology